Search

Search Constraints

You searched for: Author/Creator Wilding, John P.H.

Search Results

5. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Issue 8 (25th August 2020)

6. Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes. Issue 1 (January 2019)

7. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Issue 15 (14th April 2020)

8. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Issue 22 (28th May 2019)

9. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Issue 21 (5th May 2022)

10. Liraglutide 3.0 mg in obese/overweight adults with or without prediabetes with baseline BMI <35 vs ≥35 kg/m2 in the SCALE Obesity and Prediabetes 56-week randomized, double-blind, placebo-controlled trial. Issue 1 (January 2019)